Brachy boost therapy should be reserved for unfavorable risk patients

The ASCENDE-RT trial showed that oncological outcomes were improved among both intermediate-risk and high-risk men who were treated with external beam radiation (EBRT) and a brachytherapy boost (LDR-BT) to the prostate and adjuvant androgen deprivation therapy (ADT) (see this link). … READ MORE …

Kaiser reports on quality of life outcomes after first-line treatment for prostate cancer

Kaiser Permanente maintains a large data registry in  order to assess the quality of outcomes over time among tens of thousands of Kaiser patients, prostate cancer patients included. … READ MORE …

New guidance on treatment of localized prostate cancer from AUA and others

Over the weekend, the American Urological Association (AUA), together with the Society for Urologic Oncology (SUO), and the American Society for Radiation Oncology (ASTRO) issued new guidance on the treatment of localized prostate cancer. … READ MORE …

Aggressive, trimodal therapy active in treatment of selected men with M1 prostate cancer

A new report in the journal Urology has shown that a subset of men with metastatic disease can be placed in long-term remission through the use of a combination of androgen deprivation therapy (ADT) + surgery + radiation therapy. … READ MORE …

“Right to try” legislation and the management of prostate cancer

As many of our readers may be aware, the “right to try” treatments using investigational new drugs outside of the clinical trials processes required by drug developers and overseen by the US Food and Drug Administration is a current “hot topic” on Capitol Hill. … READ MORE …

Revised ASCO/CCO brachytherapy guidelines

The publication of the ASCENDE-RT clinical trial (discussed here) has led to a revision in the brachytherapy guidelines (available here) issued jointly by the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO). The guidelines are for patients who choose radical therapy rather than active surveillance. … READ MORE …

US-based, Phase II trial of lutetium-177 PSMA-directed endoradiotherapy

We have been provided (by the developers) with additional information about a US-based, Phase II, clinical trial of a form of radiation therapy using the targeted agent lutetium-177 prostate-specific membrane antigen 617 (177Lu-PSMA-617) for treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …